CervoMed Presents Initial Results of Phase 2a Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Showing Positive Effects on a Key Neurodegeneration Biomarker in Late-Breaking Oral Session at ISFTD 2026
Key Highlights
- ➤NfL declined ~3.1 pg/mL over 12 weeks in Phase 2a nfvPPA trial
- ➤NfL decline reached ~5.7 pg/mL among participants at or above median baseline
- ➤24-week biomarker data expected at CTAD in November 2026
- ➤Topline clinical data expected in the first quarter of 2027
- ➤No new safety signals; one patient discontinued after asymptomatic liver enzyme elevation
Expert Statements
John Alam, M.D., Chief Executive Officer of CervoMed
“In nfvPPA, NfL levels are often elevated and correlate with disease progression,”
John Alam, M.D., Chief Executive Officer of CervoMed
“The mean reduction in NfL observed over the first 12 weeks of the study contrasts with the increases typically reported in natural history studies and is particularly notable given NfL’s long half-life.”
John Alam, M.D., Chief Executive Officer of CervoMed
“While these are early results, we believe they are highly encouraging and support continued evaluation of neflamapimod in nfvPPA.”
John Alam, M.D., Chief Executive Officer of CervoMed
“We look forward to presenting 24-week biomarker data at the Clinical Trials on Alzheimer’s Disease conference in November, followed by topline clinical data in the first quarter of 2027.”
Ian M. Grant, Assistant Professor, Neurology, Feinberg School of Medicine, Northwestern University
“nfvPPA is a rare, progressive form of dementia that takes away a person’s ability to speak, and there are currently no approved pharmacological treatment options for patients,”
Ian M. Grant, Assistant Professor, Neurology, Feinberg School of Medicine, Northwestern University
“Preclinical research links p38α to the nerve damage caused by tau, the protein most often associated with nfvPPA, which makes neflamapimod a logical drug to study.”
Ian M. Grant, Assistant Professor, Neurology, Feinberg School of Medicine, Northwestern University
“While these are early results, the reduction in NfL is intriguing, and I look forward to seeing further results from this study.”
On average, reduction in plasma neurofilament light levels was observed during the first 12 weeks of treatment, with a greater decline in participants with baseline levels at or above the median
24-week biomarker data to be presented at the Clinical Trials on Alzheimer’s Disease in November 2026; clinical data expected in the first quarter of 2027
Get started
Create a free account to read the full story.